Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

Vaccine

Volumn 31, Issue 52, 2013, Pages 6232-6238

  Steens, Anneke ^a,b   Bergsaker, Marianne A Riise ^a   Aaberge, Ingeborg S ^a   Rønning, Karin ^a   Vestrheim, Didrik F ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

13 Valent pneumococcal conjugate vaccine; 7 Valent pneumococcal conjugate vaccine; Childhood immunisation programme; Epidemiology; Indirect protection; Serotype replacement; Simpson's index of diversity; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; HUMAN; IMMUNIZATION; INCIDENCE; MEDICAL HISTORY; NORWAY; OBSERVATIONAL STUDY; PNEUMOCOCCAL INFECTION; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROTYPE; VACCINATION; VACCINE FAILURE;

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 23-VALENT POLYSACCHARIDE VACCINE; 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; CHILDHOOD IMMUNISATION PROGRAMME; EPIDEMIOLOGY; INDIRECT PROTECTION; INVASIVE PNEUMOCOCCAL DISEASE; IPD; MSIS; NIPH; NON-VACCINE SEROTYPES; NONPCV13; NONPCV7; NORWEGIAN IMMUNISATION REGISTRY; NORWEGIAN INSTITUTE OF PUBLIC HEALTH; NORWEGIAN SURVEILLANCE SYSTEM FOR COMMUNICABLE DISEASES; NVT; PCV13; PCV13-7; PCV7; PPV23; SEROTYPE REPLACEMENT; SEROTYPES NOT INCLUDED IN PCV13; SEROTYPES NOT INCLUDED IN PCV7; SIMPSON'S INDEX OF DIVERSITY; SIX ADDITIONAL SEROTYPES THAT ARE IN PCV13 BUT NOT IN PCV7; STREPTOCOCCUS PNEUMONIAE; SYSVAK; VACCINE SEROTYPES; VT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NORWAY; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84888433090     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.032     Document Type: Article

References (31)

1. Norwegian Public Health Institute: Childhood vaccination programme in Norway Report for 2011 2012, [In Norwegian].
2. Rozenbaum M.H., Boersma C., Postma M.J., Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vac 2011, 10:187-199.
3. Vestrheim D.F.S, Lovoll O., Aaberge I.S., Caugant D.A., Hoiby E.A., Bakke H., et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008, 26:3277-3281.
4. Vestrheim D.F., Hoiby E.A., Bergsaker M.R., Ronning K., Aaberge I.S., Caugant D.A. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010, 28:2214-2221.
5. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051.
6. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
7. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
8. SAGE. SAGE meeting of 8-10 November 2011: review of serotype replacement in the setting of PCV7 use and implications for the PCV10/PCV13 era. http://www.who.int/immunization/sage/SAGEReplacementReport2011FINAL_nov11.pdf.
9. Magnus M.C., Vestrheim D.F., Nystad W., Haberg S.E., Stigum H., London S.J., et al. Decline in early childhood respiratory tract infections in the norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination. Pediatr Infect Dis J 2012, 31:951-955.
10. Hammitt L.L., Bruden D.L., Butler J.C., Baggett H.C., Hurlburt D.A., Reasonover A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006, 193:1487-1494.
11. Spijkerman J., van Gils E.J., Veenhoven R.H., Hak E., Yzerman E.P., van der Ende A., et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, The Netherlands. Emerg Infect Dis 2011, 17:584-591.
12. Vestrheim D.F., Hoiby E.A., Aaberge I.S., Caugant D.A. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vac Immunol 2010, 17:325-334.
13. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease following pneumococcal vaccination: a discussion of the evidence. Lancet 2011, 378:1962-1973.
14. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196:1346-1354.
15. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. PNAS 1997, 94:6571-6576.
16. Norwegian Institute of Public Health, Norwegian surveillance system for communicable diseases (MSIS), 23-9-2011.
17. Trogstad L., Ung G., Cappelen I., Haugen I.L., Feiring B. The Norwegian immunisation register-SYSVAK. Eurosurveillance 2012, 17. pii:20147.
18. Statistics Norway Population at 1st of January in 1990 up to 2011; 24-10-2011.
19. Simpson E.H. Measurement of diversity. Nature 1949, 163:688.
20. Hanage W.P., Finkelstein J.A., Huang S.S.S, Pelton S.I., Stevenson A.E., Kleinman K., et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2010, 2:80-84.
21. Kim D.S., Shin S.H., Lee H.J., Hong Y.J., Lee S.Y., Choi K.M., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to Korean children receiving routine pediatric vaccines. Pediatr Infect Dis J 2012, 266-273.
22. Weckx L.Y., Thompson A., Berezin E.N., Faria S.M., Cunha C.A., Pride M., et al. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine 2012, 30:7566-7572.
23. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28:4192-4203.
24. Scott D.A., Komjathy S.F., Hu B.T., Baker S., Supan L.A., Monahan C.A., et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007, 25:6164-6166.
25. Nunes M.C., Madhi S.A. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vac 2011, 10:951-980.
26. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:9127-9131.
27. Kaplan S.L., Barson W.J., Lin P.L., Romero J.R., Bradley J.S., Tan T.Q., et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013, 32:203-207.
28. Park I.H., Pritchard D.G., Cartee R., Brandao A., Brandileone M.C., Nahm M.H. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007, 45:1225-1233.
29. Cooper D., Xinhong Y., Sidhu M., Nahm M.H., Fernsten P., Jansen K.U. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2012, 29:7207-7211.
30. Harboe Z.B., Benfield T.L., Valentiner-Branth P., Hjuler T., Lambertsen L., Kaltoft M., et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010, 50:329-337.
31. Annex I. Summary of product characteristics-Prevnar 13. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf.